Glucose Control Therapies


This resource on Type 1 Diabetes Research was created in partnership with JDRF, an active partner of Beyond Type 1 at the time of publication, through the JDRF – Beyond Type 1 Alliance.

Finding simpler and more advanced ways to help people living with type 1 diabetes control their blood glucose levels is one of the best ways to improve lives today. With recent advances in technology, approval of hybrid-closed loop systems and new drug classes being investigated, there has never been a better time to have diabetes. Glucose control therapy research focuses three core areas:

  • Artificial pancreas (AP) technologies such as the recently approved Control-IQ from Tandem Diabetes Care
  • Next-generation insulin classes such as ultra-fast insulin, and “smart” insulin that can automatically react to the changes in the blood glucose levels
  • Investigation into other drug classes such as SGLT inhibitors to improve blood glucose management

Helping people with type 1 diabetes (T1D) manage their blood glucose levels not only lowers the risk for future complications, it makes every day easier to get through without constantly worrying about your numbers!

Glucose Control Therapies: The Latest News

vTv Therapeutics Announces Positive Study Results of Potential First-in-Class Oral Adjunctive Therapy for T1D

On February 10, vTv Therapeutics announced positive study results from the second part of the Phase 2 Simplici-T1 Study of TTP399.MORE

JDRF CEO to Health Insurers: Cover New Technology

JDRF President & CEO Aaron Kowalski, Ph.D calls on insurers to cover FDA approved type 1 diabetes technologyMORE

Tandem’s Control-IQ Hybrid Closed Loop Approved by the FDA

The FDA announced the approval of the Control-IQ Hybrid Closed Loop System from Tandem Diabetes Care. The system sees the t:slim X2 insulin pump and Dexcom G6 continuous glucose monitor working togeth...MORE

Exciting Trial Results for Tandem’s Control-IQ Hybrid Closed Loop System

Participants using Control-IQ saw an increased time in range, lowered HbA1c, and less time in hyperglycemia and hypoglycemia.MORE

Tidepool and Medtronic Announce Collaboration on Interoperable Automated Insulin Pump

Tidepool announced that they have partnered with Medtronic to create an interoperable automated insulin pump system.MORE

European Commission Approves Zynquista, First Dual SGLT Inhibitor for T1D

Zynquista is the first dual SGLT1 and SGLT2 inhibitor approved for use in Type 1 diabetes, and the second oral medication approved for use in Type 1 diabetes. MORE

Glucose Control Therapies: Trials

To learn more about all the great T1D research being funded by JDRF, visit their research and impact page here.

WRITTEN BY BT1 Editorial Team, POSTED 03/24/20, UPDATED 01/03/23

This piece was authored collaboratively by the Beyond Type 1 Editorial Team.